Genzyme which plans to announce pivotal results from its program evaluating Campath in multiple sclerosis later this year, is also interested in broadening its portfolio in this indication, said Dr Michael Panzara.
The company remains committed to researching the drug’s effect on the autoimmune system in light of certain side-effects seen in trials, said Panzara, who is group vice president of multiple sclerosis and immune diseases at Genzyme.
Campath (alemtuzumab) is a chemotherapy drug that is currently used to treat B-cell chronic lymphocytic leukemia....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1307